BR112017023785A2 - polipeptídeos do fator de von willebrand truncados para tratar hemofilia - Google Patents

polipeptídeos do fator de von willebrand truncados para tratar hemofilia

Info

Publication number
BR112017023785A2
BR112017023785A2 BR112017023785-7A BR112017023785A BR112017023785A2 BR 112017023785 A2 BR112017023785 A2 BR 112017023785A2 BR 112017023785 A BR112017023785 A BR 112017023785A BR 112017023785 A2 BR112017023785 A2 BR 112017023785A2
Authority
BR
Brazil
Prior art keywords
von willebrand
willebrand factor
truncated von
factor polypeptides
treat hemophilia
Prior art date
Application number
BR112017023785-7A
Other languages
English (en)
Inventor
Schulte Stefan
Metzner Hubert
Pestel Sabine
Weimer Thomas
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of BR112017023785A2 publication Critical patent/BR112017023785A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a um polipeptídeo compreendendo um fator de von willebrand (fvw) truncado para uso no tratamento de um distúrbio de coagulação do sangue, em que o polipep-tídeo transporta uma porção que estende a meia-vida e é administrado em excesso molar em relação ao fator viii e/ou fvw endógeno.
BR112017023785-7A 2015-05-22 2016-05-20 polipeptídeos do fator de von willebrand truncados para tratar hemofilia BR112017023785A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15168930.4 2015-05-22
EP15168930 2015-05-22
EP16163239 2016-03-31
EP16163239.3 2016-03-31
PCT/EP2016/061443 WO2016188907A1 (en) 2015-05-22 2016-05-20 Truncated von willebrand factor polypeptides for treating hemophilia

Publications (1)

Publication Number Publication Date
BR112017023785A2 true BR112017023785A2 (pt) 2018-07-17

Family

ID=56024318

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023785-7A BR112017023785A2 (pt) 2015-05-22 2016-05-20 polipeptídeos do fator de von willebrand truncados para tratar hemofilia

Country Status (17)

Country Link
US (1) US10688157B2 (pt)
EP (1) EP3297656B1 (pt)
JP (1) JP6573989B2 (pt)
KR (1) KR20180006453A (pt)
CN (1) CN107787328B (pt)
AU (1) AU2016266627A1 (pt)
BR (1) BR112017023785A2 (pt)
CA (1) CA2986626A1 (pt)
DK (1) DK3297656T3 (pt)
ES (1) ES2774011T3 (pt)
HK (1) HK1250625A1 (pt)
IL (1) IL255652A (pt)
MX (1) MX2017014503A (pt)
RU (1) RU2017145014A (pt)
SG (2) SG11201708755WA (pt)
TW (1) TW201713685A (pt)
WO (1) WO2016188907A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018087267A1 (en) * 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
EP3641800B1 (en) * 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
KR20200100771A (ko) 2017-12-19 2020-08-26 체에스엘 베링 렝나우 아게 알킬 글리코시드에 의한 단백질 정제 및 바이러스 불활성화
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技（上海）有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
WO1999055306A1 (en) 1998-04-27 1999-11-04 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1351986A2 (en) 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
ATE463514T1 (de) 2002-04-29 2010-04-15 Sanquin Bloedvoorziening ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
AU2004309063B2 (en) 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2371856B1 (en) 2004-11-12 2022-05-18 Bayer HealthCare LLC Site-directed modification of FVIII
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
DE102005002444A1 (de) 2005-01-19 2006-07-27 Wella Ag Behälter mit einem Ventil
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2008151817A1 (en) 2007-06-13 2008-12-18 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
PL2499165T3 (pl) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane
EP3272665A1 (en) 2011-06-17 2018-01-24 Berry Plastics Corporation Insulated container
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
LT2882450T (lt) * 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
US20160207977A1 (en) * 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia
CN116731201A (zh) * 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途

Also Published As

Publication number Publication date
SG10201910896UA (en) 2020-01-30
AU2016266627A1 (en) 2018-01-18
TW201713685A (en) 2017-04-16
HK1250625A1 (zh) 2019-01-11
ES2774011T3 (es) 2020-07-16
CA2986626A1 (en) 2016-12-01
JP6573989B2 (ja) 2019-09-11
US10688157B2 (en) 2020-06-23
SG11201708755WA (en) 2017-12-28
JP2018517691A (ja) 2018-07-05
WO2016188907A1 (en) 2016-12-01
EP3297656A1 (en) 2018-03-28
CN107787328B (zh) 2021-08-06
RU2017145014A (ru) 2019-06-24
EP3297656B1 (en) 2020-01-08
US20180161402A1 (en) 2018-06-14
KR20180006453A (ko) 2018-01-17
DK3297656T3 (da) 2020-03-09
IL255652A (en) 2018-01-31
MX2017014503A (es) 2018-08-01
CN107787328A (zh) 2018-03-09

Similar Documents

Publication Publication Date Title
BR112017023785A2 (pt) polipeptídeos do fator de von willebrand truncados para tratar hemofilia
BR112017019862A2 (pt) modulação de imunidade de tumor através de liberaçâo de o2 mediada por proteína
BR112018071200A2 (pt) terapia genética para o tratamento da hemofilia a
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
CL2018001299A1 (es) Vectores virales que codifican variantes de la fviii recombinante con expresión aumentada para la terapia genetica de la hemofilia a.
PE20160769A1 (es) Vectores del factor viii del virus adeno-asociado
EA201591439A1 (ru) Препараты полипептида фактора viii
BR112018009312A2 (pt) método para promover eficiência de purificação de polipeptídeo contendo região de fc
BR112016024494A8 (pt) análogo de peptídeo e seu uso
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
BR112015031277A2 (pt) Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112017006368A2 (pt) derivados de ácido borônico
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112015017795A2 (pt) antagonistas de kv1.3 e métodos de uso
CL2018001301A1 (es) Vectores virales que codifican variantes fviii recombinante con expresión aumentada para la terapia genetica de la hemofilia a.
SG10201912768YA (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
BR112019009834A2 (pt) liberação intratecal de vírus adeno-associado recombinante que codifica a proteína de ligação metil-cpg 2
BR112018010310A2 (pt) método de produção de polipeptídeos recombinantes, fungo filamentoso, uso de construção de ácido nucleico e uso de fungo filamentoso
BR112016014601A2 (pt) Composição dermatológica, dispositivo aplicador e método para preparar uma composição dermatológica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CSL BEHRING LENGNAU AG (CH)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]